Alramadhani, D.; Aljahdali, A.S.; Abdulmalik, O.; Pierce, B.D.; Safo, M.K.
Metabolic Reprogramming in Sickle Cell Diseases: Pathophysiology and Drug Discovery Opportunities. Int. J. Mol. Sci. 2022, 23, 7448.
https://doi.org/10.3390/ijms23137448
AMA Style
Alramadhani D, Aljahdali AS, Abdulmalik O, Pierce BD, Safo MK.
Metabolic Reprogramming in Sickle Cell Diseases: Pathophysiology and Drug Discovery Opportunities. International Journal of Molecular Sciences. 2022; 23(13):7448.
https://doi.org/10.3390/ijms23137448
Chicago/Turabian Style
Alramadhani, Dina, Anfal S. Aljahdali, Osheiza Abdulmalik, B. Daniel Pierce, and Martin K. Safo.
2022. "Metabolic Reprogramming in Sickle Cell Diseases: Pathophysiology and Drug Discovery Opportunities" International Journal of Molecular Sciences 23, no. 13: 7448.
https://doi.org/10.3390/ijms23137448
APA Style
Alramadhani, D., Aljahdali, A. S., Abdulmalik, O., Pierce, B. D., & Safo, M. K.
(2022). Metabolic Reprogramming in Sickle Cell Diseases: Pathophysiology and Drug Discovery Opportunities. International Journal of Molecular Sciences, 23(13), 7448.
https://doi.org/10.3390/ijms23137448